Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARREST-BP: Nomacopan in Bullous Pemphigoid
NCT05061771Phase 3Withdrawn
- Sponsor
- Akari Therapeutics
- Start
- May 2022
- Primary completion
- Aug 2022
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 4
01
Overview
A Phase 3 trial of nomacopan in Bullous Pemphigoid (BP), sponsored by Akari Therapeutics. Planned start May 2022; status: withdrawn.
02
Drugs
nomacopan
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NCT05061771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05061771.